| abstract |
(57) Summary The present invention relates to general formula I: [wherein ring A is an optionally substituted piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; R 1 is hydrogen, CHN 2 , R, or —CH 2 Y; R 2 is an optionally substituted group selected from an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or a heterocyclylalkyl group; Y is a negative elimination R 2 is CO 2 H, CH 2 CO 2 H or an ester, amide or isostere thereof; Ar is an optionally substituted aryl group; and R 3 is hydrogen, optional Substituted with a C 1-6 alkyl, F 2 , CN, aryl, or R 3 represents an unsaturated or partially saturated 5- or 6-membered 0-2 heteroatom fused ring. Bound to Ar to form] To provide a caspase inhibitor that. The compounds of the present invention are useful for the treatment of caspase-mediated diseases in mammals. |